Upscaling Synthesis of Ordered mesoporous silica material for Drug delivery Appl...
Upscaling Synthesis of Ordered mesoporous silica material for Drug delivery Applications
FORMAC Pharmaceuticals NV is actively developing and commercialising an innovative and proprietary drug delivery technology to increase the oral bioavailability of poorly aqueous soluble drugs. Those molecules represent up to sev...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MOSUDO
Water and Drug Mobility at Silica Surfaces probed with DOSY...
185K€
Cerrado
HYMADE
Hybrid Drug Delivery Systems upon Mesoporous Materials Self...
1M€
Cerrado
CTQ2011-22707
PREPARACION DE NANOPARTICULAS SILICEAS MESOESTRUCTURADAS MOD...
195K€
Cerrado
PRE2018-086647
DISEÑO DE NANOPARTICULAS SILICEAS MESOPOROSAS PARA LA LIBERA...
93K€
Cerrado
DrugMOF
Disordered Metal-Organic Frameworks for Drug Delivery
231K€
Cerrado
PTQ-13-06247
DESARROLLO DE NUEVAS MICROPARTÍCULAS PARA USO FARMACÉUTICO
29K€
Cerrado
Información proyecto USODA
Duración del proyecto: 6 meses
Fecha Inicio: 2015-05-01
Fecha Fin: 2015-11-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
FORMAC Pharmaceuticals NV is actively developing and commercialising an innovative and proprietary drug delivery technology to increase the oral bioavailability of poorly aqueous soluble drugs. Those molecules represent up to seventy percent of the compounds in discovery pipelines and up to forty percent of the currently marketed drugs. Based on the use of Ordered Mesoporous Silica (OMS) materials, FORMAC’s platform enables clients’ molecules to be formulated as oral drug products for early development, life cycle management or generic development. FORMAC is key leader in this emerging field with more than twenty different collaboration agreements and fifty molecules tested. Together with its validation in a human clinical setting, numerous regulatory consultations on EU level have been conducted. FORMAC is now ready to secure its first licensing deal with a pharmaceutical or generic company. However, some remaining challenges are hampering full deployment of FORMAC’s technology platform. Given its development stage, the company is still facing (i) an unfavourable cost of goods profile linked to the current OMS synthesis process and (ii) its limited manufacturing scale. The current proposal will unlock the first limitation and create possibilities for further upscaling. FORMAC’s ultimate goal is to bring OMS based drug delivery to the global market.